Pharmacokinetics of dextromethorphane in rats pretreated with methamphetamine and fluoxetine

DOSTÁLEK, Miroslav, Jiří SLÍVA, Eva HADAŠOVÁ a Josef TOMANDL. Pharmacokinetics of dextromethorphane in rats pretreated with methamphetamine and fluoxetine. Bratislavské lekárské listy. Bratislava: Slovak Academic Press, s.r.o. Bratislava, 2002, roč. 103, č. 9, s. 310-310. ISSN 0006-9248.

Základní údaje

Originální název

Pharmacokinetics of dextromethorphane in rats pretreated with methamphetamine and fluoxetine

Název česky

Vliv ,etamfetaminu a fluoxetinu na farmakokinetiku dextrometorfanu

Autoři

DOSTÁLEK, Miroslav (203 Česká republika), Jiří SLÍVA (203 Česká republika), Eva HADAŠOVÁ (203 Česká republika, garant) a Josef TOMANDL (203 Česká republika)

Vydání

Bratislavské lekárské listy, Bratislava, Slovak Academic Press, s.r.o. Bratislava, 2002, 0006-9248

---

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14110/02:00006927

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

dextromethorphane; fluoxetine; methamphetamine

Štítky

dextromethorphane, fluoxetine, methamphetamine

---

Anotace

V originále

The purpose of this study was to assess pharmacokinetics of dextromethorphan (model substrate of metabolism by CYP 450). Dextromethorphan was used as surrogate marker of CYP2D1 activity as it is preferentially metabolised via O-demethylation by CYP2D1 to its primary metabolite dextrorphan (DOR). CYP3A4 is responsible for N-demethylation of DEM to methoxymorphinan and of DOR to hydroxymorphinan. CYP2D1 is the homolog of human CYP2D6. Fluoxetine has been reported to be of therapeutic benefit in the treatment of alcoholism; it was the aim of the present study to compare the effect of fluoxetine (20mg/kg for 6 days i.p.)in the rats pretreated by methamphetamine (10mg/kg for 6 days i.p.), as well as to answer the question if fluoxetin may be used for the characterization of novel pharmacotherapy in methamphetamine dependence. Fluoxetine in our experiments inhibited metabolism by the CYP2D1 and the CYP3A4. Methamphetamine stimulated metabolism mediated by the CYP2D1 but not by the CYP3A4. Combination of drugs inhibited oxidative metabolism by the CYP2D1 but stimulate alternative pathway of metabolism by the CYP3A4. The results suggest that fluoxetine therapy in methamphetamine dependence could slow down biodegradation of methamphetamine and this would enable to reduce methamphetamine doses without a decrease in psychotropic effect of the drug.

Česky

The purpose of this study was to assess pharmacokinetics of dextromethorphan (model substrate of metabolism by CYP 450). Dextromethorphan was used as surrogate marker of CYP2D1 activity as it is preferentially metabolised via O-demethylation by CYP2D1 to its primary metabolite dextrorphan (DOR). CYP3A4 is responsible for N-demethylation of DEM to methoxymorphinan and of DOR to hydroxymorphinan. CYP2D1 is the homolog of human CYP2D6. Fluoxetine has been reported to be of therapeutic benefit in the treatment of alcoholism; it was the aim of the present study to compare the effect of fluoxetine (20mg/kg for 6 days i.p.)in the rats pretreated by methamphetamine (10mg/kg for 6 days i.p.), as well as to answer the question if fluoxetin may be used for the characterization of novel pharmacotherapy in methamphetamine dependence. Fluoxetine in our experiments inhibited metabolism by the CYP2D1 and the CYP3A4. Methamphetamine stimulated metabolism mediated by the CYP2D1 but not by the CYP3A4. Combination of drugs inhibited oxidative metabolism by the CYP2D1 but stimulate alternative pathway of metabolism by the CYP3A4. The results suggest that fluoxetine therapy in methamphetamine dependence could slow down biodegradation of methamphetamine and this would enable to reduce methamphetamine doses without a decrease in psychotropic effect of the drug.